Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

193

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Sacituzumab Govitecan-hziy (SG)
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Gilead Sciences

Collaborators

[object Object]